Change over period: —
NSE · ARTEMISMED
ARTEMISMED
-6.3% from the 52-week high · +67.1% above the low
Artemis Medicare Services Ltd. provides health care services. The company employs 1,789 full-time employees The company went IPO on 2020-01-23. The firm is expertized in the spectrum of advanced medical and surgical interventions, a mix of inpatient and outpatient services. The firm offers treatment facilities for various medical conditions under various specialties, which include allergy and immunology, blood (haematology), bones, muscles and joints (orthopaedics), brain, spine and nervous system, cancer (oncology), circulatory (vascular), dermatology, digestive (gastroenterology), endocrine, diabetes and metabolismheart (cardiology), infectious diseases, kidneys (renal), lung (pulmonary), mouth, teeth and face (oral and maxillofacial), obstetrics and gynaecology, psychiatry, rheumatology (arthritis and joint disease), surgery and urology. The firm's subsidiary includes Artemis Cardiac Care Private Limited.
The short version. ARTEMISMED reported revenue of ₹311 crore for Sep 2026, up 13.1% from a year earlier. Net profit was ₹31 crore (up 3.3% year on year). Return on equity was 11.1% in Mar 2026. Promoter holding was 58.39% in Sep 2026, down 8.78 points over 8 quarters.
1 · The price
How has the stock traded?
ARTEMISMED trades 6.3% below its 52-week high and 67.1% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹311 cr.
Sep 2026 net profit of ₹31 cr.
0.9 pts lower than a year earlier.
Revenue compounded at 14.3% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 311 | 287 | 279 | 272 | 275 | 255 | 240 | 232 |
| Net profit | 31 | 31 | 30 | 22 | 30 | 21 | 23 | 21 |
| Net margin % | 10.0 | 10.9 | 10.8 | 8.2 | 10.9 | 8.3 | 9.6 | 8.9 |
| EPS (₹) | 1.96 | 1.98 | 1.9 | 1.41 | 2.16 | 1.53 | 1.67 | 1.5 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|---|
| Revenue | 1081 | 937 | 879 | 737 | 555 | 408 | 565 |
| Net profit | 104 | 83 | 49 | 39 | 32 | 6 | 20 |
| Net margin % | 9.6 | 8.8 | 5.6 | 5.2 | 5.7 | 1.5 | 3.5 |
| EPS (₹) | 6.55 | 6.0 | 3.62 | 2.88 | 2.4 | 0.47 | 1.5 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 11.1% in Mar 2026; debt to equity is 0.24.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 11.1 | 9.9 | 11.0 | 9.6 |
| Return on capital % | 13.7 | 12.2 | 12.7 | 10.1 |
| EBITDA margin % | 19.3 | 19.1 | 15.8 | 13.6 |
| Net margin % | 9.3 | 8.5 | 5.5 | 5.2 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 14.3% | 21.9% |
| Profit CAGR | 39.0% | 75.9% |
4 · The owners
Who holds it, and are they adding?
Down 8.78 pts over 8 quarters.
Up 11.82 pts over 8 quarters.
Down 2.59 pts over 8 quarters.
+2 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 67.17 | 67.17 | 66.53 | 66.53 | 58.39 | 58.39 | 58.39 | 58.39 | -8.78 |
| FII | 0.64 | 0.31 | 0.24 | 0.37 | 12.47 | 12.19 | 12.29 | 12.46 | +11.82 |
| DII | 4.5 | 5.04 | 4.76 | 4.27 | 2.91 | 2.89 | 2.4 | 1.91 | -2.59 |
| Public | 20.6 | 20.39 | 21.46 | 21.81 | 20.08 | 20.37 | 20.76 | 21.08 | +0.48 |
Mutual fund holdings · Oct 2026
9 schemes hold this stock
7 the month before.
- HSBC Focused Fund2.17% of NAV
- JM ELSS - Tax Saver Fund1.47% of NAV
- Groww BSE Hospitals ETF0.66% of NAV
- Motilal Oswal BSE Healthcare ETF0.09% of NAV
- Bandhan BSE Healthcare Index Fund0.09% of NAV
- Motilal Oswal BSE 1000 Index Fund0.01% of NAV
- ADITYA BIRLA SUN LIFE BSE TOTAL MARKET ETF0.01% of NAV
- ADITYA BIRLA SUN LIFE BSE TOTAL MARKET INDEX FUND0.01% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for ARTEMISMED are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Healthcare Services stocks
Quick answers
Common questions about ARTEMISMED
What is the ARTEMISMED share price?
ARTEMISMED (ARTEMISMED) last closed at ₹340.00, down 0.99% on the day. Its 52-week range is ₹205.51 to ₹366.60.
What is the market cap of ARTEMISMED?
ARTEMISMED has a market capitalisation of about ₹5,435 crore. Its price-to-earnings ratio is 47.6.
How are ARTEMISMED's latest results?
ARTEMISMED reported revenue of ₹311 crore for Sep 2026, up 13.1% from a year earlier. Net profit was ₹31 crore (up 3.3% year on year). Return on equity was 11.1% in Mar 2026. Promoter holding was 58.39% in Sep 2026, down 8.78 points over 8 quarters.
Who owns ARTEMISMED?
As of Sep 2026, shareholding was: Promoter 58.39%, FII 12.46%, DII 1.91%, Public 21.08%.
How many mutual funds hold ARTEMISMED?
9 mutual fund schemes held ARTEMISMED in October 2026. That compares with 7 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 10 Jul 2026 · Final Dividend - Rs. 0.45
- 11 Jul 2025 · Final Dividend - Rs. 0.45
- 05 Jul 2024 · Final Dividend - Rs. 0.45
- 14 Jul 2023 · Dividend - Rs. 0.45
- 23 Sep 2021 · Stock Split From Rs.10/- to Rs.1/-
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.